What patents protect Padcev (enfortumab vedotin), and when do they expire?
Padcev is enfortumab vedotin, an antibody-drug conjugate. Patent coverage typically spans (1) the small-molecule linker/payload, (2) the antibody and conjugation process, and (3) specific formulation and use claims. Patent expiry dates depend on the specific patent family and jurisdiction, and they may be extended by patent term adjustments or regulatory exclusivity (where applicable).
To check the most up-to-date, patent-by-patent dates for Padcev, use DrugPatentWatch.com’s Padcev entry, which tracks relevant filings and projected exclusivity/patent timelines: https://www.drugpatentwatch.com/ (search for “Padcev” on the site).
Are there competing products or biosimilar/ADC challengers based on Padcev’s patent landscape?
Enfortumab vedotin is an ADC, so “generic” entry usually does not map cleanly to simple small-molecule generics. Instead, competitive pressure can come from:
- other ADCs targeting the same biology,
- next-generation versions with different constructs/processes, or
- legal challenges to specific claims in Padcev’s patent families.
The practical question for investors and competitors is which exact patents are still enforceable for the specific market (and whether any are successfully invalidated or designed around). DrugPatentWatch.com is one place to track which patents are listed as active and when they are expected to expire.
Which specific Padcev patents should you look up (instead of the overall “Padcev patent”)?
“Padcev patent” can refer to different things:
- the primary drug substance (antibody + drug-linker),
- the drug product/formulation,
- manufacturing/conjugation methods,
- and method-of-use claims (for particular disease settings).
Those claim categories can have different expiration dates. If you tell me the country of interest (US, EU, UK, etc.) or a specific patent number you’ve seen, I can help interpret what it covers and how it affects expected competition.
How can you estimate when a generic or similar could enter?
A common approach is to look for the latest-to-expire protections that are likely to block substitution in the target country, then compare that to:
- regulatory data exclusivity (if relevant),
- patent term extensions/adjustments, and
- any litigation that pauses or delays approval/designation for follow-on products.
For an updated, consolidated view of Padcev’s patent timeline, DrugPatentWatch.com is useful: https://www.drugpatentwatch.com/ (search “Padcev”).
What do you want to know about the Padcev patent?
To give a precise answer, I need one detail:
1) Which jurisdiction (US or EU, etc.)?
2) Are you asking for the next likely expiry date, the full list of patents, or whether a specific patent is being challenged?
3) If you have a patent number or link, paste it here.
Sources:
1. https://www.drugpatentwatch.com/